RxDoctor Payments Data

George Paroulek, MD

Internal Medicine · Secaucus, NJNPI 1821026782

Payments from drug & device makers

$1,671in general payments, 2019–2025

Across 64 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$758
  • AstraZeneca$134
  • AbbVie$97
  • Novo Nordisk$77
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58
  • Genentech USA, Inc.$53
  • plus $494 from 19 others

What the payments were for

  • Food & beverage$91355%
  • Gifts$75845%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,671 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$101,957
Medicare patients
495
Services billed
4,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$12,744
SymbicortBudesonide/Formoterol Fumarate12$3,674
CefuroximeCefuroxime Axetil241$3,647
Cefdinir48$979
Albuterol Sulfate HfaAlbuterol Sulfate42$774
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$650
Atorvastatin Calcium62$636
Doxycycline Hyclate61$619
Levothyroxine Sodium36$456
Metoprolol Succinate29$453
Rosuvastatin Calcium28$402
Ciprofloxacin Hcl55$390
Losartan Potassium26$369
Amlodipine Besylate49$361
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$12,74411 claims
AstraZenecaSymbicort$134$3,67412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Secaucus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →